University of Connecticut School of Medicine

Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

Retrieved on: 
Thursday, October 5, 2023
Health, FDA, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Annual general meeting, Constipation, Columbia University Vagelos College of Physicians and Surgeons, Functional constipation, Division, Gastrointestinal disease, Drug development, Treatment, Diarrhea, Food and Drug Administration, Society, University, Ironwood Pharmaceuticals, Columbia University, AbbVie, Hospital, Defecation, Patient, Education, Head, Clinical trial, University of Connecticut School of Medicine, Medication, Bisacodyl, PDT, Physician, Research, Surgeon, Pharmaceutical industry, Birth control, Nursing, Ironwood, Pediatrics, Hepatology, Nutrition

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a leading global gastrointestinal healthcare company, will present findings during the 2023 North American Society for Pediatric Gastroenterology, Hepatology & Nutrition (NASPGHAN) Annual Meeting demonstrating that linaclotide decreased the use of rescue medications in children and adolescents ages 6-17 years-old with functional constipation.

Key Points: 
  • Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a leading global gastrointestinal healthcare company, will present findings during the 2023 North American Society for Pediatric Gastroenterology, Hepatology & Nutrition (NASPGHAN) Annual Meeting demonstrating that linaclotide decreased the use of rescue medications in children and adolescents ages 6-17 years-old with functional constipation.
  • The analysis found that approximately half of the children enrolled in the trial relied on rescue medications at least once per week for symptom relief.
  • The symposium, which is not an official NASPGHAN event/function, will provide meeting attendees with an overview of pediatric functional constipation, presentation/diagnosis and management.
  • The post-hoc analysis demonstrated that in pediatric patients with functional constipation, diarrhea occurred in 7.4 percent of the linaclotide-treated population and 1.5 percent of those receiving placebo.

Michael S. Aronow, MD, Installed as AOFAS® President

Retrieved on: 
Friday, September 22, 2023
Ankle, Society, American Orthopaedic Foot and Ankle Society, University, Friends, Hartford, Connecticut, Postgraduate education, Foot, Clinical Information Technology Program Office, National Joint Apprenticeship and Training Committee, American Academy, Research, Medicine, Mentorship, Harvard Medical School, American Medical Association, Harborview Medical Center, MD, Patient, Physician, Specialty Society Relative Value Scale Update Committee, University of Connecticut School of Medicine, Sports medicine, Management, Nursing, Dentistry

Rosemont, Ill., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Orthopaedic foot and ankle surgeon, Michael S. Aronow, MD, was named the president of the American Orthopaedic Foot & Ankle Society (AOFAS), the leading organization for the surgical and nonoperative treatment of the foot, ankle, and lower extremity.

Key Points: 
  • Rosemont, Ill., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Orthopaedic foot and ankle surgeon, Michael S. Aronow, MD, was named the president of the American Orthopaedic Foot & Ankle Society (AOFAS), the leading organization for the surgical and nonoperative treatment of the foot, ankle, and lower extremity.
  • In addition to leading the Society as president, Dr. Aronow will serve on the Board of Directors of the Orthopaedic Foot & Ankle Foundation , the philanthropic arm of AOFAS.
  • As president of the 2,500-member society, Dr. Aronow’s main goal is to continue to move the AOFAS toward achieving its vision to lead the global community in foot and ankle education, research, innovation, and advocacy.
  • Dr. Aronow is well known in organized medicine for his tireless advocacy on behalf of orthopaedic foot and ankle surgeons and their patients.

Reproductive Endocrinologist Eric Han, M.D., Joins Texas Fertility Center San Antonio

Retrieved on: 
Tuesday, July 25, 2023
Endometriosis, Yale School of Medicine, University, Woman, Infertility, Research, Yale school, TFC, IVF, Patient, Physician, Nursing, Frustration, Yale University, British Nuclear Medicine Society, University of Connecticut School of Medicine, Birth control

San Antonio, July 25, 2023 (GLOBE NEWSWIRE) -- Texas Fertility Center (TFC) is pleased to announce that reproductive endocrinologist Eric Han, M.D., is joining its San Antonio office.

Key Points: 
  • San Antonio, July 25, 2023 (GLOBE NEWSWIRE) -- Texas Fertility Center (TFC) is pleased to announce that reproductive endocrinologist Eric Han, M.D., is joining its San Antonio office.
  • As a highly trained reproductive endocrinologist, Eric Han, M.D., provides patients with all the comprehensive services that Texas Fertility Center San Antonio offers, helping people move beyond the frustration of infertility to the joy of parenthood.
  • He says, “I’m looking forward to working with the tremendous staff, including the physicians, nurses and support staff, at Texas Fertility Center San Antonio.
  • It’s an honor and a privilege to work with this great group of people to provide the finest fertility care.”
    Eric Han, M.D., is now accepting new patients at Texas Fertility Center San Antonio.

Ramon W. Johnson, M.D., M.B.A, Becomes ABEM President

Retrieved on: 
Monday, July 24, 2023
Ohio State University, HealthPartners, Saint Anne, Denver Health Medical Center, Emergency medicine, University, Pediatrics, ABEM, Doctor, Professional, American Board of Emergency Medicine, Multimedia, University of Arizona College of Medicine – Tucson, Mel, Global Health, American Board of Commissioners for Foreign Missions, Regions Hospital, Banner University Medical Center Tucson, Public health, University of Colorado School of Medicine, Medical director, Patient, Division, Executive Committee, Mission Hospital (Mission Viejo, California), Hospital, S-1 Executive Committee, University of Connecticut School of Medicine, St. Anne's Hospital, Biostatistics, Management, Epidemiology

EAST LANSING, Mich., July 24, 2023 /PRNewswire/ -- Ramon W. Johnson, M.D., M.B.A., is the new President of the American Board of Emergency Medicine (ABEM).

Key Points: 
  • EAST LANSING, Mich., July 24, 2023 /PRNewswire/ -- Ramon W. Johnson, M.D., M.B.A., is the new President of the American Board of Emergency Medicine (ABEM).
  • "It is an incredible honor to represent ABEM as a community physician.
  • Continuing to set the highest standards for knowledge assessment and professionalism for all emergency physicians will benefit our patients and the specialty."
  • Dr. Kendall is Professor of Emergency Medicine and Vice Chair of Education at the University of Colorado School of Medicine.

The Inner Circle Acknowledges, Joe Littlejohn, Jr as a Top Pinnacle Professional for his contributions to the field of Medical Technology and Urology

Retrieved on: 
Friday, June 16, 2023
Male, Telehealth, Society, Howard University Hospital, Paruresis, Neurogenic bladder dysfunction, Gland, University, National Medical Association, Test management, University of Connecticut Health Center, EMR, Health technology, Data collection, American Urological Association, Penn State Health Children's Hospital, Medicine, DEI, Privacy, Christianity, Assistant, Inner circle, American Board of Commissioners for Foreign Missions, Patient, Love, Specialization, Ureter, NewYork-Presbyterian Hospital, General surgery, Department of Urology, University of Virginia, HPI, University of Connecticut School of Medicine, Health, Hospital, System, Female, Prostate cancer, Nursing, Medical imaging, Urology

MECHANICSBURG, Pa., June 16, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Joe Littlejohn, Jr. is acknowledged as a Top Pinnacle Professional for his contributions to the field of Medical Technology and Urology.

Key Points: 
  • MECHANICSBURG, Pa., June 16, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Joe Littlejohn, Jr. is acknowledged as a Top Pinnacle Professional for his contributions to the field of Medical Technology and Urology.
  • According to the doctor, urology is the branch of medicine that focuses on surgical and medical diseases of the male and female urinary-tract system and the male reproductive organs.
  • Aside from his medical career, Dr. Littlejohn, Jr. serves as an Assistant Professor of Surgery within the Department of Urology at Penn State Health Milton S. Hershey Medical Center.
  • The doctor offers his services at Penn State Health Surgery Specialties (Hershey Pennsylvania) & Penn State Health Medical Group Camp Hill Specialties.

Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics

Retrieved on: 
Wednesday, May 31, 2023
University, Internal medicine, Myriad Genetics, FACP, Brigham and Women's Hospital, MYGN, Research, University of Pittsburgh School of Medicine, SALT, Doctor of Philosophy, Oncology, Harvard Medical School, Genetics, MD, Genetic testing, Growth, Hospital, Association for Molecular Pathology v. Myriad Genetics, Inc., University of Connecticut School of Medicine, Wilfrid Sellars, Dana–Farber Cancer Institute, Nursing, Medicine

SALT LAKE CITY, May 31, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has named Adam Brufsky, MD, PhD, FACP, as Scientific Advisor to its oncology business unit.

Key Points: 
  • SALT LAKE CITY, May 31, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has named Adam Brufsky, MD, PhD, FACP, as Scientific Advisor to its oncology business unit.
  • In his new role, Dr. Brufsky is responsible for guiding clinical development and medical affairs to further elevate Myriad’s Precise™ Oncology Solutions portfolio.
  • “Adam is an accomplished leader and respected expert in the field of medical oncology and brings a unique combination of academic, research and clinical experience to Myriad,” said Michael Lyons, general manager of oncology, Myriad Genetics.
  • He is board-certified in internal medicine and medical oncology.

Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week® 2023

Retrieved on: 
Monday, May 8, 2023
Teens, Children, FDA, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Consumer, Health, Nutrition, University, Ironwood Pharmaceuticals, Gastrointestinal disease, University of Connecticut School of Medicine, Head, Safety, Constipation, Ageing, Gastroenterology, Functional constipation, Medication, DDW, SBM, Defecation, Patient, Division, Birth control, Linaclotide, Pediatrics

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, presented findings during the 2023 Digestive Disease Week® (DDW) meeting from a Phase III clinical trial on the potential of linaclotide for children and adolescents ages 6-17 years-old with functional constipation.

Key Points: 
  • Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, presented findings during the 2023 Digestive Disease Week® (DDW) meeting from a Phase III clinical trial on the potential of linaclotide for children and adolescents ages 6-17 years-old with functional constipation.
  • Ironwood had previously announced topline data from this study in September 2022.
  • Linaclotide was generally well-tolerated and exhibited a safety profile consistent with a prior pediatric Phase II study in functional constipation.
  • Linaclotide-treated patients demonstrated a greater than two-fold least squares mean change from baseline in SBMs/week (2.220) compared to placebo (1.050) (p

DermaSensor’s Non-Invasive Skin Cancer Device Found to Halve the Number of Skin Cancers Not Referred by PCPs

Retrieved on: 
Thursday, May 4, 2023
Technology, Medical Devices, General Health, Hospitals, Science, Medical Supplies, Clinical Trials, FDA, Biotechnology, Health, Other Science, Research, Other Technology, Other Health, Hardware, Practice Management, Oncology, Melanoma, Basal-cell carcinoma, Carcinoma, ESS, Skin cancer, Mayo Clinic, University of Connecticut School of Medicine, University, Patient, PCP, Skin, Medical imaging

Of the two studies presented, one demonstrated the standalone performance of the hand-held, non-invasive device, and the other evaluated the impact of the device on PCPs’ management of skin cancer.

Key Points: 
  • Of the two studies presented, one demonstrated the standalone performance of the hand-held, non-invasive device, and the other evaluated the impact of the device on PCPs’ management of skin cancer.
  • The ESS device achieved device sensitivity superior to that of the PCPs (95.5% vs. 83.0%, p-value
  • When unaided by the device the PCPs only correctly referred 82.0% of cancerous lesions, whereas when the PCPs were equipped with the device result they correctly referred 91.4% of skin cancers.
  • "As skin cancer rates continue to rise, the need for accurate and efficient skin cancer detection in primary care is increasingly important.

Dahlia Philips, M.D., Named Medical Director of MetroPlusHealth's Partnership in Care (PIC) Special Needs Plan

Retrieved on: 
Monday, February 13, 2023
Medical director, Science, Partnerships in Care, Internal medicine, Nursing care plan, American Board of Internal Medicine, COVID-19, Virtue, George Washington University, Patient, HIV/AIDS, New Yorker, Infection, University, HIV, Health, University of Connecticut School of Medicine, American Board of Commissioners for Foreign Missions, B.A, PIC, Education, Summit Health, Partnership, Mount Sinai Beth Israel, Quality of life, Dr. Ramune: Mysterious Disease Specialist, MD, Nursing, Pharmaceutical industry, New York University

NEW YORK, Feb. 13, 2023 /PRNewswire/ -- MetroPlusHealth , New York City's high-quality, affordable health plan, today announced the appointment of Dahlia Philips, M.D., as Medical Director of the plan's Partnership in Care (PIC) Special Needs Plan.

Key Points: 
  • NEW YORK, Feb. 13, 2023 /PRNewswire/ -- MetroPlusHealth , New York City's high-quality, affordable health plan, today announced the appointment of Dahlia Philips, M.D., as Medical Director of the plan's Partnership in Care (PIC) Special Needs Plan.
  • "We are excited to welcome Dr. Dahlia Philips to the diverse PIC care team at MetroPlusHealth.
  • "As a native New Yorker, I am thrilled to join a team of stellar colleagues striving to serve the diverse communities of New York City as the Medical Director of the Partnership in Care division at MetroPlusHealth," said Dr. Dahlia Philips.
  • Dr. Philips, a highly respected and experienced physician, has nearly two decades of proven expertise in infectious disease, acute care and critical care.

CAN Community Health Names Dr. Steven Barnett Chief Medical Officer

Retrieved on: 
Monday, November 7, 2022
Leadership, Family medicine, Hepatitis C, Medical director, Education, University of Connecticut Health Center, Pharmacy, Case management, STD, Yale University, Clemson University, Biology, University, Interim, Health, Mental health, University of Connecticut School of Medicine, Pleasure, Patient, MD, Medical device, Microbiology

SARASOTA, Fla., Nov. 7, 2022 /PRNewswire-PRWeb/ -- CAN Community Health (CAN) has appointed Steven Barnett, MD as Chief Medical Officer. Dr. Barnett joined the healthcare nonprofit in 2017 at its Columbia, South Carolina clinic. His role was later expanded to serve as Medical Director of CAN clinics in South Carolina, Virginia, and New Jersey. He has served as Interim Chief Medical Officer since August 2022. Dr. Barnett will step into his permanent role immediately, and beginning January 1, 2023, Dr. Barnett will also oversee all dental services provided by CAN.

Key Points: 
  • CAN Community Health (CAN) has appointed Steven Barnett, MD as Chief Medical Officer.
  • Dr. Barnett joined the healthcare nonprofit in 2017 and has served as Interim Chief Medical Officer since August 2022.
  • SARASOTA, Fla., Nov. 7, 2022 /PRNewswire-PRWeb/ -- CAN Community Health (CAN) has appointed Steven Barnett, MD as Chief Medical Officer.
  • He has served as Interim Chief Medical Officer since August 2022.